Celcuity (CELC) Gains from Sales and Divestitures (2018 - 2025)
Celcuity (CELC) reported Gains from Sales and Divestitures of $1079.0 for Q4 2025, down 53.25% on a YoY basis from $2308.0 in Q4 2024, and down 36.86% quarter-over-quarter from $1709.0 in Q3 2025.
Celcuity (CELC) Gains from Sales and Divestitures (2018 - 2025) Analysis & Trends
Celcuity has reported Gains from Sales and Divestitures for 7 years, with the latest figure at $1079.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 53.25% year-over-year to $1079.0; the trailing twelve-month figure through Dec 2025 stood at $1079.0 (down 53.25% YoY), and the FY2025 full-year result was $1079.0, down 53.25% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $1079.0, down from $1709.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $15686.0 in Q2 2021, with the low at $250.0 in Q3 2022.
- Historically, Gains from Sales and Divestitures has averaged $4402.4 across 5 years, with a median of $2636.0 in 2022.
- Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures plunged 81.1% — and 2023, when it climbed 10.43%.
- Celcuity's Gains from Sales and Divestitures stood at $15686.0 in 2021, then sank by 79.51% to $3214.0 in 2022, then rose by 1.84% to $3273.0 in 2023, then slipped by 29.48% to $2308.0 in 2024, then plunged by 53.25% to $1079.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $1079.0 (Q4 2025), $1709.0 (Q3 2025), and $1079.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,079.00 |
| Dec 31, 2025 | 1,079.00 |
| Sep 30, 2025 | 1,709.00 |
| Sep 30, 2025 | 1,709.00 |
| Jun 30, 2025 | 1,079.00 |
| Jun 30, 2025 | 1,079.00 |
| Dec 31, 2024 | 2,308.00 |
| Dec 31, 2024 | 2,308.00 |
| Jun 30, 2024 | 2,308.00 |
| Jun 30, 2024 | 2,308.00 |
| Dec 31, 2023 | 3,273.00 |
| Dec 31, 2023 | 3,273.00 |
| Jun 30, 2023 | 3,273.00 |
| Jun 30, 2023 | 3,273.00 |
| Dec 31, 2022 | 3,214.00 |
| Dec 31, 2022 | 3,214.00 |
| Sep 30, 2022 | 250.00 |
| Sep 30, 2022 | 250.00 |
| Jun 30, 2022 | 2,964.00 |
| Jun 30, 2022 | 2,964.00 |